CVMP Approves New Veterinary Medicines During October Meeting
The Committee for Veterinary Medicinal Products has issued positive opinions on several veterinary medicines, including vaccines and treatments for dogs.
Bovilis Lumpyvax vaccine approved for lumpy skin disease in cattle.
Stemyca receives authorization for treating chronic inflammatory enteropathy in dogs.
Vetmedin's benefit-risk balance deemed positive for proposed indication.
The Committee for Veterinary Medicinal Products (CVMP) convened from October 6 to 8, 2026, where it issued several significant opinions regarding veterinary medicinal products. Among the notable decisions, the committee granted a positive opinion for the Bovilis Lumpyvax vaccine, aimed at immunizing cattle against lumpy skin disease, thereby reducing clinical symptoms and viral presence in affected animals.
In addition to the bovine vaccine, the CVMP also approved Stemyca, a treatment involving equine umbilical cord mesenchymal stem cells. This product is intended to alleviate clinical signs of non-food-responsive chronic inflammatory enteropathy (CIE) in dogs, marking a significant advancement in veterinary care for this condition.
The committee further reviewed Mirataz, a mirtazapine-based product, and approved updates to its product information based on new safety data. These updates indicate that overdosing on Mirataz may lead to known adverse effects, such as skin reactions at the application site. Furthermore, the CVMP recommended a one-year extension of the marketing authorization for Vaxxitek HVT+IBD+H5, an avian influenza vaccine, under exceptional circumstances.
In a related procedure, the CVMP concluded its review of Vetmedin, an oral solution for dogs. Despite initial disagreements among member states regarding its efficacy, the committee, after thorough evaluation, determined that the benefit-risk balance for the proposed indication remains favorable. The findings will be forwarded to the European Commission for further consideration.
The CVMP also addressed scientific inquiries, adopting reports on pharmaceutical and immunological products for Atlantic salmon. Additionally, it classified a new antiparasitic product for dogs as intended for a limited market, thus not eligible for authorization under current regulations. The committee's ongoing pharmacovigilance efforts were highlighted, with updates on signal management processes available through the IRIS public portal, ensuring transparency and accessibility of information regarding veterinary medicines.
